Plotkin SA - Search Results

1

Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA. Krause PR, et al. Among authors: plotkin sa. Vaccine. 2013 Dec 17;32(1):4-10. doi: 10.1016/j.vaccine.2013.09.042. Epub 2013 Oct 13. Vaccine. 2013. PMID: 24129123 Free PMC article. Review.

2

Cytomegalovirus vaccine development--past and present.

Plotkin SA. Plotkin SA. Transplant Proc. 1991 Jun;23(3 Suppl 3):85-9. Transplant Proc. 1991. PMID: 1648842 Review. No abstract available.

3

The status of cytomegalovirus vaccine.

Starr SE, Friedman HM, Plotkin SA. Starr SE, et al. Among authors: plotkin sa. Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S964-5. doi: 10.1093/clind/13.supplement_11.s964. Rev Infect Dis. 1991. PMID: 1664136 Review.

4

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.

Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. Plotkin SA, et al. Ann Intern Med. 1991 Apr 1;114(7):525-31. doi: 10.7326/0003-4819-114-7-525. Ann Intern Med. 1991. PMID: 1848053 Clinical Trial.

5

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.

Gonczol E, Ianacone J, Ho WZ, Starr S, Meignier B, Plotkin S. Gonczol E, et al. Vaccine. 1990 Apr;8(2):130-6. doi: 10.1016/0264-410x(90)90135-9. Vaccine. 1990. PMID: 2159679

6

Progress in vaccine development for prevention of human cytomegalovirus infection.

Gönczöl E, Plotkin S. Gönczöl E, et al. Curr Top Microbiol Immunol. 1990;154:255-74. doi: 10.1007/978-3-642-74980-3_10. Curr Top Microbiol Immunol. 1990. PMID: 2161323 Review. No abstract available.

7

Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants.

Clark HF, Borian FE, Modesto K, Plotkin SA. Clark HF, et al. Among authors: plotkin sa. Vaccine. 1990 Aug;8(4):327-32. doi: 10.1016/0264-410x(90)90089-5. Vaccine. 1990. PMID: 2168607

8

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.

Plotkin SA, Starr SE, Friedman HM, Gönczöl E, Weibel RE. Plotkin SA, et al. J Infect Dis. 1989 May;159(5):860-5. doi: 10.1093/infdis/159.5.860. J Infect Dis. 1989. PMID: 2540247

9

Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate.

Gönczöl E, Berensci K, Pincus S, Endresz V, Méric C, Paoletti E, Plotkin SA. Gönczöl E, et al. Among authors: plotkin sa. Vaccine. 1995 Aug;13(12):1080-5. doi: 10.1016/0264-410x(95)00048-6. Vaccine. 1995. PMID: 7491815

10

The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response.

Berencsi K, Gönczöl E, Endresz V, Kough J, Takeda S, Gyulay Z, Plotkin SA, Rando RF. Berencsi K, et al. Among authors: plotkin sa. Vaccine. 1996 Apr;14(5):369-74. doi: 10.1016/0264-410x(95)00227-r. Vaccine. 1996. PMID: 8735546

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

566 results

Search Page